← All trials
NCT04624672
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Nov 12, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Geisinger ClinicLead sponsor
- Novo NordiskCollaborator
- Geisinger ClinicOverall official - principal investigator
- Geisinger ClinicReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.